

GALECTIN THERAPEUTICS INC  
Form 8-K  
August 21, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **August 16, 2013**

**GALECTIN THERAPEUTICS INC.**

(Exact name of registrant as specified in its charter)

**Nevada**  
(State or Other Jurisdiction  
of Incorporation)

**001-31791**  
(Commission File Number)

**04-3562325**  
(IRS Employer  
Identification No.)

Edgar Filing: GALECTIN THERAPEUTICS INC - Form 8-K

**4960 PEACHTREE INDUSTRIAL BOULEVARD, Ste 240**

**NORCROSS, GA 30071**

**(Address of principal executive office) (zip code)**

Registrant's telephone number, including area code: **(678) 620-3186**

**N/A**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ..  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ..  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ..  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ..  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**SECTION 3 SECURITIES AND TRADING MARKETS**

**Item 3.02 Unregistered Sales of Equity Securities.**

On August 16, 2013, Galectin Therapeutics Inc. ( Galectin ) entered into an agreement to sell 500,000 shares of its common stock in an unregistered, private placement for \$3,000,000. The transaction was completed on August 20, 2013. The sale was made to a single investor pursuant to an exemption from registration in accordance with Section 4(a)(2) of the Securities Act of 1933, as amended.

On August 21, 2013, Galectin issued a press release announcing the transaction, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.

**SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS**

**Item 9.01 Financial Statements and Exhibits.**

(a) Financial Statements of Businesses Acquired.  
Not applicable.

(b) Pro Forma Financial Information.  
Not applicable.

(c) Shell Company Transactions.  
Not applicable.

(d) Exhibits.

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release dated August 21, 2013

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Galectin Therapeutics Inc.

Date: August 21, 2013

By: /s/ Jack W. Callicutt  
Jack W. Callicutt

Chief Financial Officer